Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 06:59 ET | Source: Research and Markets

2025 Chemotherapy Induced Anemia (CIA) Pipeline Landscape Report Featuring Analysis of Roxadustat (FibroGen) and SPP-003 (SBI Pharmaceuticals)

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Chemotherapy Induced Anemia - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
February 21, 2025 07:15 ET | Source: Research and Markets

Cancer Supportive Care Market Growth Trends & Challenges, 2025-2030 - Personalized and Home-Based Cancer Supportive Care Expands Amid Cost and Access Challenges

Dublin, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The "Cancer Supportive Care - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Cancer Supportive...
May 31, 2024 06:26 ET | Source: Research and Markets

Chemotherapy-Induced Anemia Pipeline Insights Report, 2024 Featuring Analysis of Roxadustat (FibroGen), SPP-003 (SBI Pharmaceuticals), and More

Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy-Induced Anemia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
March 26, 2024 07:00 ET | Source: FibroGen, Inc.

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd...
November 04, 2019 07:00 ET | Source: FibroGen, Inc

FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019

SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November...
September 26, 2019 07:00 ET | Source: FibroGen, Inc

FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy

SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class...